Status:

COMPLETED

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease

Lead Sponsor:

Panion & BF Biotech Inc.

Conditions:

Hyperphosphatemia

End Stage Renal Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of the study is to determine the effect and optimum dose and evaluate the safety of ferric citrate, administered three times daily (TID) immediately after meals for a total daily dose of 4...

Eligibility Criteria

Inclusion

  • Age\>18 years and has a diagnosis of ESRD
  • On a three-times per week hemodialysis regimen
  • On a stable dose of a phosphate-binding agent for at least one month prior to study entry.
  • If on vitamin D supplementation or calcitriol, must be on a stable dose for at least one month prior to study entry.
  • Hct \>= 20%
  • Serum Ca level of 8 mg/dL to 10.5 mg/dL

Exclusion

  • Is pregnant or lactating
  • Clinically significant GI disorder
  • Has tertiary hyperparathyroidism or is immediately post-operative from a parathyroidectomy (within the first 3 months post-op or the plasma Ca is \<7 mg/dL)
  • ferritin\>800 ng/mL
  • Unstable medical condition unsuitable for the study in the opinion of investigator
  • Has been treated with an investigational agent within 30 days of enrollment
  • Has a history of documented iron allergy or hemochromatosis

Key Trial Info

Start Date :

June 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

183 Patients enrolled

Trial Details

Trial ID

NCT01503736

Start Date

June 1 2010

Last Update

January 13 2020

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang-Gung Memorial Hospital

Kaohsiung City, Taiwan

2

Division of Nephrology, Keelung Chang Gung Memorial Hospital

Keelung, Taiwan

3

Division of Nephrology, Department of Internal Medicine, Far East Memorial Hospital

New Taipei City, Taiwan

4

Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital

Taichung, Taiwan

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease | DecenTrialz